Cationic Lipopolymer Nucleic Acid Complexes Prevent Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Synthetic gene delivery systems face challenges with poor stability and low transfection efficiency due to DNA aggregation, especially at high concentrations required for clinical applications, limiting their commercialization and efficacy.
Innovation Solution
The development of stable and concentrated nucleic acid formulations using a cationic lipopolymer comprising a cationic polymer backbone with cholesterol and polyethylene glycol, which allows for high nucleic acid concentrations without aggregation, enabling efficient lyophilization and reconstitution while maintaining biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If DNA formulations are prepared at high concentrations required for optimal clinical dosing, then dosing flexibility and treatment efficacy are improved, but formulation stability deteriorates due to DNA aggregation over time
Solution Approach 1:
The patent introduces cationic lipopolymers as intermediary substances that mediate between DNA molecules to prevent aggregation. These lipopolymers form stable complexes with DNA through electrostatic interactions, acting as a protective intermediary layer that maintains formulation stability at high DNA concentrations without requiring dilution or cryoprotectants
2Duration of action of stationary object
If conventional lyophilization methods are used to improve long-term stability, then shelf life is extended, but transfection activity is lost due to alteration of physicochemical properties and aggregation upon reconstitution
Solution Approach 1:
The patent applies parameter changes by optimizing lyophilization conditions specifically for cationic lipid-DNA complexes, controlling temperature, pressure, and drying rate parameters to preserve the physicochemical integrity of the complexes. This allows lyophilization to extend shelf life while maintaining transfection activity upon reconstitution
3Reliability
If cationic lipid-based gene delivery complexes are used to improve transfection efficiency, then delivery efficiency is enhanced, but formulation stability worsens due to particle rupture, fusion, or dissociation
Solution Approach 1:
The patent employs composite materials by combining cationic lipids with specific polymers to create lipopolymer-DNA complexes. This composite structure integrates the transfection efficiency of cationic lipids with the stability of polymer-DNA complexes, preventing particle rupture, fusion, or dissociation while maintaining high transfection efficiency
4Adaptability or versatility
If oxidative hydrolysis occurs in delivery vectors to modify chemical structure, then chemical diversity is increased, but particle instability increases contributing to aggregation
Solution Approach 1:
The patent converts the potentially harmful effect of oxidative hydrolysis into a beneficial feature by designing delivery vectors with controlled chemical modifications that enhance stability. Specifically, the lipopolymer structure is engineered to resist unwanted oxidation while allowing controlled hydrolysis that improves solubility and stability without causing aggregation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach provides stable and biologically active nucleic acid formulations that can be efficiently lyophilized and reconstituted to high concentrations, enhancing transfection efficiency and dosing flexibility, overcoming previous limitations in synthetic gene delivery systems.
Implementation Method 1
comprising a cationic lipopolymer and at least about 0.5 mg/ml of a nucleic acid, wherein the mixture is complexed
Implementation Method 2
Freeze-drying is a useful method for improving long-term stability of a number of drug pharmaceuticals
Data Source
AI summary
Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.